Disease · MONDO_0001106
Comparisons in its trials21
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 21
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| ACE-I + Placebo vs ACE-I + ARB: serious adverse events | 88 of 242 | 88 of 244 | 486 | NCT01885559 | Trial comparisons |
| ACE-I + Placebo vs ACE-I + ARB: Number of Participants With 50% Reduction of Baseline eGFR, End Stage Renal Disease (ESRD, Initiation of Dialysis or Preemptive Transplant), or Death. | 116 of 242 | 115 of 243 | 485 | NCT01885559 | Trial comparisons |
| Sparsentan vs Irbesartan: deaths from any cause | 0 of 202 | 1 of 202 | 404 | NCT03762850 | Trial comparisons |
| Sparsentan vs Irbesartan: serious adverse events | 75 of 202 | 71 of 202 | 404 | NCT03762850 | Trial comparisons |
| Terlipressin vs Placebo: deaths from any cause | 41 of 97 | 45 of 99 | 196 | NCT01143246 | Trial comparisons |
| Terlipressin vs Placebo: serious adverse events | 62 of 93 | 59 of 95 | 188 | NCT01143246 | Trial comparisons |
| Tacrolimus Plus MMF Plus Steroids vs Tacrolimus Plus Rapamycin Plus Steroids: deaths from any cause | 16 of 86 | 15 of 84 | 170 | NCT00533442 | Trial comparisons |
| Tacrolimus Plus MMF Plus Steroids vs Tacrolimus Plus Rapamycin Plus Steroids: serious adverse events | 40 of 86 | 38 of 84 | 170 | NCT00533442 | Trial comparisons |
| Arm A (BBD) vs Arm B (BTD): deaths from any cause | 7 of 16 | 2 of 15 | 31 | NCT02424851 | Trial comparisons |
| Arm A (BBD) vs Arm B (BTD): Overall Survival | 9 of 16 | 13 of 15 | 31 | NCT02424851 | Trial comparisons |
| Arm A (BBD) vs Arm B (BTD): serious adverse events | 11 of 16 | 9 of 15 | 31 | NCT02424851 | Trial comparisons |
| Arm A (BBD) vs Arm B (BTD): Number of Participants With >50% Reduction From Baseline in Serum Free Light Chain | 13 of 16 | 3 of 14 | 30 | NCT02424851 | Trial comparisons |
| Calcineurin Inhibitor and Mycophenolic Acid vs Everolimus and Mycophenolic Acid: deaths from any cause | 0 of 12 | 0 of 12 | 24 | NCT01936519 | Trial comparisons |
| Calcineurin Inhibitor and Mycophenolic Acid vs Everolimus and Mycophenolic Acid: serious adverse events | 0 of 12 | 1 of 12 | 24 | NCT01936519 | Trial comparisons |
| Cohort A: Lumasiran vs Cohort B: Lumasiran: deaths from any cause | 0 of 6 | 0 of 15 | 21 | NCT04152200 | Trial comparisons |
| Cohort A: Lumasiran vs Cohort B: Lumasiran: serious adverse events | 1 of 6 | 8 of 15 | 21 | NCT04152200 | Trial comparisons |
| Cystagon® vs RP103: serious adverse events | 0 of 9 | 0 of 9 | 18 | NCT00872729 | Trial comparisons |
| Vasopressin vs Normal Saline Placebo: Count of Patient Who Need Vasopressers in the Perioperative Period | 3 of 8 | 4 of 10 | 18 | NCT00886262 | Trial comparisons |
| Vasopressin vs Normal Saline Placebo: Count of Participants Who Needed Diuretics Postoperatively | 4 of 8 | 1 of 10 | 18 | NCT00886262 | Trial comparisons |
| Vasopressin vs Normal Saline Placebo: deaths from any cause | 0 of 8 | 0 of 10 | 18 | NCT00886262 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0001106/comparisons